Mike Dyson is Head of the Antibody Discovery and Engineering Department at Ichnos Glenmark Innovation, responsible for the development of novel multi-specific immune engager therapeutics to treat cancer. Mike is an experienced project manager, leading multi-disciplinary teams for several successful therapeutic antibody drug discovery projects resulting in 9 biologics (antibody or bi-specific format) to commence human clinical trials or approaching IND filing to treat cancer or auto-immune diseases. Projects collaborations included Janssen, Takeda, BMS, Sanofi, Teva, F-star, Adaptate, GammaDelta, Epsilogen, Astria, Agenus, INOTREM, LG Chem, Generium, plus one third of the top 20 Pharma. He has experience in co-founding start-up companies, being a key founding team member during their growth phase and operating as an R&D manager in more mature, larger publicly listed companies in addition to VC backed companies. He has published 40 papers and book chapters (cited over 2000 times, h-index 20) and is inventor on 16 patent and patent applications mainly focussed on novel antibody therapeutics, antibody formats or discovery platforms. Previous posts held by Mike include CTO and co-founder of IONTAS Ltd, a therapeutic antibody discovery and development company, Head of Protein Engineering at Acambis plc (acquired by Sanofi) and was a Project Leader at the Wellcome Trust Sanger Institute. He has extensive experience in the multi-disciplinary enabling antibody discovery and development technologies including library generation, antibody and scaffold phage and mammalian display, in silico design and engineering, assay development, cell line engineering, protein sciences and pre-clinical development. He has successfully applied for several grants from the EU, UK and various charities. He has a PhD in organic synthetic chemistry from the University of Birmingham and has held research posts at the Massachusetts Institute of Technology and the Universities of Edinburgh and Cambridge.